Positive Phase III results demonstrate efficacy of Avycaz
2 September 2015 | By Victoria White
Positive results from RECAPTURE 1 and 2, Phase III studies evaluating the antibiotic Avycaz as a treatment for patients with cUTI, have been announced...
List view / Grid view
News
FDA accepts supplemental Biological License Application for Opdivo
2 September 2015 | By Victoria White
The FDA has accepted for filing and review the supplemental Biological licence Application for Opdivo for the treatment of patients with non-squamous NSCLC...
Coulter Partners announces further expansion of Nordics team
2 September 2015 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointments of Nicolaj Moerk Thomsen as Senior Consultant and Lisbeth Holm as Research Associate in their new Copenhagen offices...
Allergan acquires Naurex; strengthens mental health pipeline
2 September 2015 | By Victoria White
Allergan has completed the acquisition of Naurex, a biopharmaceutical company developing therapies for challenging disorders of the central nervous system...
Heart failure medicine LCZ696 to be available to the NHS
2 September 2015 | By Victoria White
Heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the MHRA Early Access to Medicines Scheme...
NICE draft guidance conditionally recommends Vimizim
2 September 2015 | By Victoria White
NICE has provisionally recommended BioMarin’s Vimizim for the treatment of the very rare inherited lysosomal storage disease, mucopolysaccharidosis type IVa...
BMS gets exclusive rights to acquire Promedior
2 September 2015 | By Victoria White
As well as granting exclusive rights to acquire Promedior, the agreement grants Bristol-Myers Squibb worldwide rights to Promedior's lead asset PRM-151.
FDA grants priority review for Empliciti Biologics License Application
2 September 2015 | By Victoria White
The FDA has accepted for priority review the BLA for Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy...
TECOS analysis adds heart failure data for sitagliptin
2 September 2015 | By Victoria White
New TECOS study findings have shown that patients with type-2 diabetes can safely take sitagliptin without an increased risk of cardiovascular complications...
New technology allows unattended sampling and synthesis of chemical reactions
1 September 2015 | By Mettler Toledo
The new EasySampler Connectivity Kit enables integration of EasySampler and the associated sampling information with the touchscreen of METTLER TOLEDO Reactor Systems for Chemical Synthesis and Automated Jacketed Lab Reactor Control. EasySampler data is automatically transferred to, and reported with, the referring experiment to enable unattended sampling and synthesis of…
Sartorius Stedim Biotech and GE Healthcare sign worldwide OEM supply agreement
Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industries and GE Healthcare’s Life Sciences business, a provider of start-to-finish enterprise solutions, technologies and services for biopharmaceutical manufacturing, today announced they have entered into a worldwide OEM supply agreement for Sartorius Stedim Biotech’s innovative membrane adsorber purification technology, Sartobind™.
ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim
1 September 2015 | By Charlotte Batchelor
Four grants will be awarded to independent research projects, focused on improving patient outcomes in thromboembolic diseases
Sticky honey helps icky acne
1 September 2015 | By Charlotte Batchelor
Large clinical trial shows that a New Zealand kanuka honey formulation helps acne...
European marketing authorisation granted for Alexion’s Kanuma™ (sebelipase alfa)
1 September 2015 | By Nick Jackson
Alexion Pharmaceuticals, Inc. has announced that the European Commission has approved Kanuma™ (sebelipase alfa) for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency...
Abbott announces positive results of its naturally dissolving stent from ABSORB Japan study
1 September 2015 | By Nick Jackson
Abbott has announced positive one-year clinical results from ABSORB Japan, a multi-center, randomised trial comparing the safety and effectiveness of Abbott's fully dissolving AbsorbTM heart stent to XIENCE®...
